Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Kathyrn Morton, Neeraj Agarwal, Umang Swami, Kenneth M. Boucher, Benjamin L. Maughan, Adam Kessel, Roberto Nussenzveig, Taylor Ryan McFarland, Andrew W. Hahn, Manish Kohli, Benjamin Haaland, Deepika Sirohi, John M. Hoffman, Nicolas Sayegh
Publikováno v:
Oncologist
Lessons Learned Background Previously, we showed the combination of radium-223 and enzalutamide to be safe and associated with improved efficacy based on a concomitant decline in serum bone metabolism markers compared with enzalutamide alone in a pha
Autor:
Steven Lemery, Vadryn Pierre, Kirsten B. Goldberg, Richard Pazdur, Lisa Rodriguez, Anuja Patel, Youwei Bi, Sandra Casak, Lorraine Pelosof, Jeanne Fourie Zirkelbach, Amy E. McKee, Xiaoping Jiang, Jiang Liu, Patricia Keegan
Publikováno v:
The Oncologist
Regorafenib is the first drug approved by the FDA for the treatment of hepatocellular carcinoma that has progressed on sorafenib and is expected to become a standard of care for these patients. This article summarizes the FDA's review of the data sub
Autor:
Lijuan Chen, Beihui Huang, Meilan Chen, Wenming Chen, Ying Feng, Junru Liu, Xiaozhe Li, Jianyong Li, Juan Li, Jingli Gu, Yin Wu, Baijun Fang
Publikováno v:
The Oncologist
The identification of prognostic factors for multiple myeloma is important. This article focuses on the prognostic value of 1q21 gain in a Chinese population according to different treatment regimens and accompanying high‐risk factors.
Backgro
Backgro
Autor:
Takashi Morimoto, Taroh Satoh, Yoshito Komatsu, Hajime Takikawa, Naoya Yamazaki, Kenichi Sugihara, Toshirou Nishida, Takayuki Yoshino, Masayuki Chosa, Kei Muro, Yoko Hamada, Toshiyuki Sunaya, Hiroyuki Uetake, Kensei Yamaguchi
Publikováno v:
The oncologist. 24(7)
Background Regorafenib improved the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) who progress after standard therapies in two phase III trials. The present large-scale prospective observational study evaluated the safety
Autor:
Kristie Lawhorn, Kenneth R. Hess, Mohammed A. Habra, Aung Naing, David S. Hong, Siqing Fu, Helen X. Chen, Lawrence A. Doyle, Razelle Kurzrock, Patricia LoRusso, Naifa L. Busaidy
Publikováno v:
The oncologist. 20(7)
Background. Cixutumumab (a humanized monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]) and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus were combined in a phase I study of patients with advanced cancer. We
Autor:
Aman U. Buzdar
Publikováno v:
The Oncologist. 8:335-341
Learning Objectives After completing this course, the reader will be able to: Define appropriate candidates for various endocrine therapies. Discuss the choices of therapies for patients with advanced breast cancer. Assess the options for adjuvant en
Autor:
Charles A. Leath, Larry C. Kilgore, Rodney P. Rocconi, Warner K. Huh, Mack N. Barnes, Ronald D. Alvarez, J. Michael Straughn, Edward E. Partridge
Publikováno v:
The oncologist. 11(4)
Objective. To assess the feasibility of using pegylated liposomal doxorubicin (PLD) as a consolidation therapy in patients with advanced ovarian cancer who have attained a clinically defined complete response to initial platinum/paclitaxel-based chem
Publikováno v:
The oncologist. 8(4)
On May 5, 2003, gefitinib (Iressa®, ZD1839) 250-mg tablets received accelerated approval by the U.S. Food and Drug Administration as monotherapy treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after fail